A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT

Journal:
Blood
Published:
DOI:
10.1182/blood.2025031053
Affiliations:
14
Authors:
35
Go to article
Institutions Authors Share
Vor Biopharma, United States of America (USA)
22.000000
22.000000
22.000000
 0.63
University of Kansas Medical Center (KUMC), United States of America (USA)
1.000000
 0.03
Washington University in St. Louis (WUSTL), United States of America (USA)
1.000000
 0.03
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)
1.000000
 0.03
UH Seidman Cancer Center, CWRU, United States of America (USA)
1.000000
 0.03
Miami Cancer Institute, United States of America (USA)
1.000000
 0.03
Moores Cancer Center, United States of America (USA)
1.000000
 0.03
University of Minnesota (UMN), United States of America (USA)
1.000000
 0.03
University of Michigan (U-M), United States of America (USA)
1.000000
 0.03
The University of Utah (Utah), United States of America (USA)
1.000000
 0.03
Emory University, United States of America (USA)
1.000000
 0.03
NIH National Cancer Institute (NCI), United States of America (USA)
1.000000
 0.03
Hackensack University Medical Center (Hackensack UMC), United States of America (USA)
1.000000
 0.03
Stanford University, United States of America (USA)
1.000000
 0.03
Interested in Oncology and Carcinogenesis?